Interleukin Genetics

Interleukin Genetics developed and marketed proprietary genetic tests focused on chronic inflammatory diseases and health-related conditions. Their main offerings included tests for periodontal disease susceptibility, cardiovascular risk, bone health, weight management, general nutrition needs, and overall wellness. The company leveraged expertise in genetics of inflammation/metabolism to provide actionable insights for personalized healthcare. They operated a CLIA-certified lab in Waltham, MA. Facing financial difficulties from declining sales and inability to secure further funding or strategic partnerships led them to wind down operations in mid-to-late 2017; their assets were subsequently acquired by Orig3n.